Pemvidutide
Dual glucagon and GLP-1 receptor agonist. Once weekly.
Catalog reviewed Oct 13, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
What to know about Pemvidutide
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
- FDA shortage report
- In development
Investigational. Not FDA-approved.
- Route & frequency
- Once weekly
Investigational uses
Pemvidutide (investigational)
MASH (investigational)
A glucagon/GLP-1 dual agonist engineered with a balanced ratio intended to drive liver-fat and weight reduction while preserving lean mass, the same dual-agonist mechanism as survodutide.
Dosing, warnings & contraindications
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
Pemvidutide is investigational. See its registered studies below. Search DailyMed.
Clinical trials
8 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.
- Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASHNCT07795164PHASE3Recruiting1,800 enrolled
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711PHASE2Completed212 enrolled
- RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860PHASE2Active_not_recruiting121 enrolled
- RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects…NCT06987513PHASE2Completed100 enrolled
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityNCT04561245PHASE1Completed100 enrolled
- ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885PHASE1Completed95 enrolled
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911PHASE1Completed64 enrolled
- Pemvidutide (ALT-801) DDI Study in Healthy VolunteersNCT04972396PHASE1Completed40 enrolled
Source: ClinicalTrials.gov API v2 · as of Oct 19, 2026
All trials on ClinicalTrials.gov